Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma
{{output}}
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. C... ...
